Standout Papers

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxor... 2004 2026 2011 2018 1.3k
  1. Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer (2004)
    E O’Brien, Nely Wigler et al. Annals of Oncology

Immediate Impact

8 by Nobel laureates 16 from Science/Nature 74 standout
Sub-graph 1 of 18

Citing Papers

Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironment
2024 Standout
A smart mask for exhaled breath condensate harvesting and analysis
2024 StandoutScience
2 intermediate papers

Works of E O’Brien being referenced

Use of exhaled breath condensate (EBC) in the diagnosis of SARS-COV-2 (COVID-19)
2020
Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer
2004 Standout

Author Peers

Author Last Decade Papers Cites
E O’Brien 698 1045 846 95 3.8k
Frederick G.P. Welt 356 1076 557 72 3.5k
László Rosivall 686 690 308 158 4.8k
William K. Vaughn 652 1435 353 133 6.6k
Haim Danenberg 346 886 197 125 3.3k
Daohai Yu 671 358 1326 170 5.3k
Hui Zheng 868 644 1291 179 6.3k
Helmut Geiger 588 1228 462 182 5.8k
Constantin von zur Mühlen 583 890 170 139 3.5k
Wei Chen 662 1836 340 174 6.3k
José Antonio Rodríguez 392 447 287 140 3.8k

All Works

Loading papers...

Rankless by CCL
2026